Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) was the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 14,800 shares, a drop of 50.3% from the July 15th total of 29,800 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 22,900 shares, the short-interest ratio is presently 0.6 days.
Barinthus Biotherapeutics Stock Down 0.4 %
BRNS traded down $0.00 during trading on Wednesday, reaching $1.32. 4,365 shares of the stock traded hands, compared to its average volume of 20,976. The stock’s 50-day moving average is $1.51 and its 200 day moving average is $2.18. Barinthus Biotherapeutics has a 12 month low of $1.21 and a 12 month high of $5.10. The stock has a market capitalization of $51.52 million, a PE ratio of -0.75 and a beta of -0.52.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.01). As a group, equities research analysts anticipate that Barinthus Biotherapeutics will post -1.9 EPS for the current year.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Barinthus Biotherapeutics
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Catalina Capital Group LLC acquired a new position in shares of Barinthus Biotherapeutics during the second quarter valued at about $25,000. Ipswich Investment Management Co. Inc. bought a new stake in Barinthus Biotherapeutics in the 2nd quarter valued at about $32,000. BlueCrest Capital Management Ltd acquired a new position in Barinthus Biotherapeutics during the 1st quarter worth approximately $1,292,000. DC Funds LP bought a new position in Barinthus Biotherapeutics in the first quarter worth approximately $1,528,000. Finally, Alphabet Inc. acquired a new stake in Barinthus Biotherapeutics in the second quarter valued at approximately $2,119,000. 25.20% of the stock is owned by institutional investors.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Recommended Stories
- Five stocks we like better than Barinthus Biotherapeutics
- Stock Market Upgrades: What Are They?
- Brinker International’s Price Dip is an Appetizing Entry Point
- What is a Special Dividend?
- 3 Stocks That Could Beat the September Blues
- Stock Average Calculator
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.